Mahajan et al., 1999 - Google Patents
Rational design and synthesis of a novel anti-leukemic agent targeting Bruton′ s tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2, 5 …Mahajan et al., 1999
View HTML- Document ID
- 6529103850932968674
- Author
- Mahajan S
- Ghosh S
- Sudbeck E
- Zheng Y
- Downs S
- Hupke M
- Uckun F
- Publication year
- Publication venue
- Journal of Biological Chemistry
External Links
Snippet
In a systematic effort to design potent inhibitors of the anti-apoptotic tyrosine kinase BTK (Bruton′ s tyrosine kinase) as anti-leukemic agents with apoptosis-promoting and chemosensitizing properties, we have constructed a three-dimensional homology model of …
- 108010029445 Agammaglobulinaemia Tyrosine Kinase 0 title abstract description 219
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mahajan et al. | Rational design and synthesis of a novel anti-leukemic agent targeting Bruton′ s tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl) propenamide] | |
| US6160010A (en) | BTK inhibitors and methods for their identification and use | |
| EP1071658B1 (en) | Btk inhibitors and methods for their identification and use | |
| US6204267B1 (en) | Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds | |
| Vassilev et al. | Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex | |
| Grosskopf et al. | Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo | |
| Pianetti et al. | Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-α that can be inhibited by the tumor suppressor PTEN | |
| M Scott et al. | Targeting protein tyrosine phosphatases for anticancer drug discovery | |
| Magnuson et al. | Why target PIM1 for cancer diagnosis and treatment? | |
| Holder et al. | Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase | |
| Kurokawa et al. | A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53 | |
| Baffi et al. | Protein kinase C quality control by phosphatase PHLPP1 unveils loss-of-function mechanism in cancer | |
| Zou et al. | Activated SRC oncogene phosphorylates R-ras and suppresses integrin activity | |
| Qiu et al. | Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors | |
| US20110008347A1 (en) | Cancer-related protein kinases | |
| Zhang et al. | Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors | |
| Park et al. | Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms | |
| Fabini et al. | Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends | |
| Couñago et al. | Structural characterization of human Vaccinia-Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations | |
| Vanderpool et al. | Characterization of the CHK1 allosteric inhibitor binding site | |
| Brough et al. | Application of off-rate screening in the identification of novel pan-isoform inhibitors of pyruvate dehydrogenase kinase | |
| Chen et al. | Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity | |
| Zhu et al. | Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth | |
| Wang et al. | Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers | |
| Chen et al. | Design, Synthesis, and Evaluation of Non‐ATP‐Competitive Small‐Molecule Polo‐Like Kinase 1 (Plk1) Inhibitors |